Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.

Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.

mTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Sutherland, A, Akhtar, M, Zilvetti, M, Brockmann, J, Ruse, S, Fuggle, S, Sinha, S, Harden, P, Friend, P
Natura:	Conference item
Pubblicazione:	2014

Documenti analoghi

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
di: Flechner, S, et al.
Pubblicazione: (2005)

Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
di: Trzonkowski, P, et al.
Pubblicazione: (2008)

ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
di: Muthusamy, A, et al.
Pubblicazione: (2011)

Systematic reviews of alemtuzumab in renal transplantation.
di: O'Callaghan, J, et al.
Pubblicazione: (2013)

Systematic reviews of alemtuzumab in renal transplantation
di: O'Callaghan, J, et al.
Pubblicazione: (2013)

Alemtuzumab induction and steroid free immunosupprssion in pancreas transplantation.
di: Muthusamy, A, et al.
Pubblicazione: (2007)

Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
di: Muthusamy, A, et al.
Pubblicazione: (2008)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
di: Haynes, R, et al.
Pubblicazione: (2014)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
di: Haynes, R, et al.
Pubblicazione: (2014)

Steroid-free immunosuppression in pancreas transplantation using Alemtuzumab induction
di: Muthusamy, A, et al.
Pubblicazione: (2007)

Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.
di: Plata-Munoz, J, et al.
Pubblicazione: (2009)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
di: Watson, C, et al.
Pubblicazione: (2004)

Elective conversion to sirolimus vs. continued tacrolimus in kidney transplantation (the 3c study): Results of a randomized trial
di: Haynes, R, et al.
Pubblicazione: (2017)

Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation
di: Brook, MO, et al.
Pubblicazione: (2024)

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
di: Haynes, R, et al.
Pubblicazione: (2014)

Alemtuzumab: right drug, right dose?
di: Haynes, R, et al.
Pubblicazione: (2011)

Liver transplantation from non-heart-beating donors: current status and future prospects.
di: Reddy, S, et al.
Pubblicazione: (2004)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
di: Phuong-Thu T Pham, et al.
Pubblicazione: (2008-12-01)

Risk factors for delayed graft function defined as need for dialysis or failure of creatinine to fall by 10% in the first 24 hours after transplant.
di: Stratopoulos, C, et al.
Pubblicazione: (2008)

Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
di: Carroll, R, et al.
Pubblicazione: (2013)

Application of operational tolerance signatures are limited by variability and type of immunosuppression in renal transplant recipients: A cross-sectional study.
di: Bottomley, M, et al.
Pubblicazione: (2016)

PRE-TRANSPLANT ASSESSMENT FOR LIVING DONOR RENAL TRANSPLANTATION: EVALUATION OF THE XM-ONE ASSAY
di: Procter, J, et al.
Pubblicazione: (2009)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
di: Clatworthy, MR, et al.
Pubblicazione: (2009)

Risk analysis for deterioration of renal function after pancreas alone transplant.
di: Chatzizacharias, N, et al.
Pubblicazione: (2012)

Terapia de indução com alentuzumabe em receptores de transplante renal Alemtuzumab induction in kidney transplant recipients
di: Edison Luiz Mandia Sampaio, et al.
Pubblicazione: (2010-03-01)

Reversible sirolimus-induced pulmonary alveolar proteinosis in a renal transplant patient
di: David Eugenio Hinojosa-González, et al.
Pubblicazione: (2020-01-01)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
di: Watson, C, et al.
Pubblicazione: (2005)

Our Unique Experience with Low-Dose Alemtuzumab as an Induction Agent for Renal Transplantation: A Case Series
di: Cherin Josi, et al.
Pubblicazione: (2024-12-01)

Normothermic presevation and transplantation of heart-beating-donor porcine livers.
di: Reddy, S, et al.
Pubblicazione: (2005)

Evaluation of the XM-ONE assay and the role of endothelial cell antibodies in recipients of living donor renal transplants
di: Procter, J, et al.
Pubblicazione: (2009)

Conversion to Combined Therapy with Sirolimus and Mycophenolate Mofetil Improved Renal Function in Stable Renal Transplant Recipients
di: Meng-Kun Tsai, et al.
Pubblicazione: (2007-05-01)

Impact of immunosuppression on the incidence of early subclinical renal allograft rejection: implications for protocol biopsy policy.
di: Roberts, I, et al.
Pubblicazione: (2009)

Prevalence of nonmalignant cutaneous disease in renal transplant recipients
di: Lally, A, et al.
Pubblicazione: (2006)

Evaluation of the XM-ONE (R) assay and the role of endothelial cell antibodies in recipients of living donor renal transplants
di: Procter, J, et al.
Pubblicazione: (2009)

Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
di: Morgan, R, et al.
Pubblicazione: (2012)

Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients
di: Joel D. Morrisett, et al.
Pubblicazione: (2002-08-01)

Update on the long-term complications of renal transplantation.
di: Bottomley, M, et al.
Pubblicazione: (2013)

Expanded criteria donors in pancreas transplantation: The Oxford experience
di: Muthusamy, A, et al.
Pubblicazione: (2009)

Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients
di: Lung-Chih Li, et al.
Pubblicazione: (2017-04-01)

Alemtuzumab Plus Cyclosporine Treatment of the Autoimmune Hemolytic Anemia in an Adult Bowel Transplant
di: A. Lauro, et al.
Pubblicazione: (2014-01-01)